1. Home
  2. TSLX vs XERS Comparison

TSLX vs XERS Comparison

Compare TSLX & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sixth Street Specialty Lending Inc.

TSLX

Sixth Street Specialty Lending Inc.

HOLD

Current Price

$18.69

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

N/A

Current Price

$8.47

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TSLX
XERS
Founded
2010
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.5B
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
TSLX
XERS
Price
$18.69
$8.47
Analyst Decision
Buy
Buy
Analyst Count
9
6
Target Price
$21.61
$10.83
AVG Volume (30 Days)
486.3K
1.6M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
10.82%
N/A
EPS Growth
N/A
100.00
EPS
0.15
N/A
Revenue
N/A
$49,590,000.00
Revenue This Year
N/A
$34.37
Revenue Next Year
$1.20
$22.86
P/E Ratio
$125.33
N/A
Revenue Growth
N/A
142.67
52 Week Low
$16.04
$5.25
52 Week High
$24.79
$10.08

Technical Indicators

Market Signals
Indicator
TSLX
XERS
Relative Strength Index (RSI) 64.23 55.86
Support Level $18.50 $8.00
Resistance Level $19.75 $8.42
Average True Range (ATR) 0.45 0.31
MACD 0.15 -0.04
Stochastic Oscillator 83.63 90.60

Price Performance

Historical Comparison
TSLX
XERS

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: